Home > Statements & Submissions
Statements & Submissions
Statements & Submissions
JUL 24
On behalf of the biotech sector, BIOTECanada welcomes the report of the Pharmaceutical and Life Sciences Sector Task Force released today. In particular, we appreciate the clear definition of the challenges facing the sector and the roadmap it provides toward future potential solutions. There is much to do, and we urge the government to move…
Read More
Statements & Submissions
JUN 5
The federal government’s AI for All strategy is an important signal that Canada sees health and life sciences as a place where AI can drive both positive health outcomes and economic growth. To fully realize that opportunity, Canada must ensure AI-enabled life sciences innovation can be developed, protected, scaled, and commercialized here. Life sciences is where research…
Read More
Statements & Submissions
MAY 22
BIOTECanada responds to pre-budget consultations in advance of the 2026 federal budget BIOTECanada’s federal budget recommendations will help place Canadian life science companies at the forefront of global industry growth and expansion. Investment and improvements to Canada’s regulatory systems will stabilize the domestic environment and protect Canada’s competitiveness by generating effective, timely and competitive guard…
Read More
Statements & Submissions
MAY 11
BIOTECanada was proud to participate in the signing of two memoranda of understanding with the Asociación Mexicana de Laboratorios Farmacéuticos (AMILAF) and La Cámara Nacional de la Industria Farmacéutica (CANIFARMA), marking an important step in deepening life sciences collaboration between Canada and Mexico. Signed as part of Mexico’s trade mission to Canada, the agreements formalize…
Read More
Statements & Submissions
MAY 6
BIOTECanada in collaboration with Innovative Medicines Canada responded to the Canadian Drug Agency's consultation on its proposed Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations. This reflects a positive step towards evolving HTA to better capture the full value of innovation by incorporating informal caregiver health-related quality of life, and patient and…
Read More
Statements & Submissions
APR 30
April 30, 2026 BIOTECanada welcomes the federal government’s 2026 Spring Economic Update as an important signal of continued progress on measures that support Canada’s life sciences sector and the conditions companies need to grow. These updates reflect constructive collaboration between government and industry, including the association’s ongoing advocacy to improve the effectiveness and accessibility of…
Read More
Statements & Submissions
APR 29
Health Canada’s work to modernize clinical trials, including clinical trial regulations and guidance on decentralized clinical trials, is a positive step toward a more modern and competitive regulatory framework. BIOTECanada supports continued engagement and encourages alignment with trusted regulators such as the FDA and EMA to reduce burden, improve efficiency, and strengthen Canada’s position as a destination for…
Read More
Statements & Submissions
APR 28
BIOTECanada welcomed Health Canada's proposal to leverage foreign regulatory authority decisions as part of the Red Tape Review initiative and recognizes this as a meaningful step toward improving timely access to medicines for Canadians. To fully realize the benefits of the Order and the reliance pathway, BIOTECanada recommended broadening the scope of the medicines considered under the Reliance…
Read More
Statements & Submissions
APR 26
For National Immunization Awareness Week and World Immunization Week, it’s an important opportunity to recognize the vital role vaccines play in protecting people, communities, and health systems. Vaccines have transformed public health, helping prevent serious illness, reduce strain on the healthcare system, and protect those most at risk. Their impact continues to be felt every…
Read More
Statements & Submissions
MAR 19
BIOTECanada welcomes the announcement of the Pharmaceutical and Life Sciences Sector Task Force and the clear recognition that a strong life sciences sector is essential to both economic growth and health outcomes in Canada. This work should remain focused on the investment and regulatory conditions needed to grow globally competitive companies, and - most importantly…
Read More
Statements & Submissions
MAR 10
BIOTECanada welcomes the launch of the National Research Council of Canada’s Biomedical Countermeasures Initiative, introduced as part of the federal government’s Defence Industrial Strategy. It is an important step in strengthening Canada’s domestic capacity to develop and manufacture diagnostics, vaccines, and therapeutics, and help move biomedical innovation into real-world solutions in response to biological threats.…
Read More
Statements & Submissions
FEB 23
The CDA-AMC has proposed to make changes to numerous aspects of the reimbursement review program. Jointly with Innovative Medicines Canada, BIOTECanada proposed to keep the current model for draft and final recommendations and refocusing the CDA-AMC reform effort on potential changes that would more directly address the current global pharmaceutical policy dynamics. Read the full statement here For…
Read More
MembershipJoin the voice of Canadian biotech
- A seat at the table in federal policy consultations
- Members-only insights, briefings, and the CEO Report
- Cost savings program with vetted industry suppliers
- Discounted access to BIONATION and Canada @ BIO
230+
- Health & pharmaceutical
- Agricultural biotechnology
- Industrial & environmental
- Emerging fields